Biofilm formation by Stenotrophomonas maltophilia:: Modulation by quinolones, trimethoprim-sulfamethoxazole, and ceftazidime

被引:136
|
作者
Di Bonaventura, G
Spedicato, A
D'Antonio, D
Robuffo, I
Piccolomini, R
机构
[1] Univ G DAnnunzio, Ctr Sci Invecchiamento, Lab 27, I-66100 Chieti, Italy
[2] Univ G DAnnunzio, Dipartimento Sci Biomed, Lab Microbiol Clin, I-66100 Chieti, Italy
[3] Univ G DAnnunzio, Ctr Sci Invecchiamento, I-66100 Chieti, Italy
[4] CNR, Ist Trapianti Organo & Immunocitol, Sez Chieti, Chieti, Italy
[5] ASL, Serv Microbiol Clin, Dipartimento Ematol & Oncol, Osped Spirito Santo, Pescara, Italy
关键词
D O I
10.1128/AAC.48.1.151-160.2004
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
We investigated the in vitro effects of seven fluoroquinolones (ciprofloxacin, grepafloxacin, levofloxacin, moxifloxacin, norfloxacin, ofloxacin, and rufloxacin), compared to those of trimethoprim-sulfamethoxazole (SXT) and ceftazidime on total biomass and cell viability of Stenotrophomonas maltophilia biofilm. S. maltophilia attached rapidly to polystyrene, within 2 h of incubation, and then biofilm formation increased over time, reaching maximum growth at 24 h. In the presence of fluoroquinolones at one-half and one-fourth the MIC, biofilm biomass was significantly (P < 0.01) reduced to 55 to 70% and 66 to 76% of original mass, respectively. Ceftazidime and SXT did not exert any activity. Biofilm bacterial viability was significantly reduced by all antibiotics tested at one-half the MIC. At one-fourth the MIC all antibiotics, except levofloxacin, significantly reduced viability. Treatment of preformed biofilms with bactericidal concentrations (500, 100, and 50 mu g/ml) of all fluoroquinolones caused, except for norfloxacin, significant reduction of biofilm biomass to 29.5 to 78.8, 64.1 to 83.6, and 70.5 to 82.8% of original mass, respectively. SXT exerted significant activity at 500 mu g/ml only. Ceftazidime was completely inactive. Rufloxacin exhibited the highest activity on preformed biofilm viability, significantly decreasing viable counts by 0.6, 5.4, and 17.1% at 500, 100, and 50 mu g/ml, respectively. Our results show that (i) subinhibitory (one-half and one-fourth the MIC) concentrations of fluoroquinolones inhibit adherence of S. maltophilia to polystyrene and (ii) clinically achievable concentrations (50 and 100 mu g/ml) of rufloxacin are able to eradicate preformed S. maltophilia biofilm.
引用
收藏
页码:151 / 160
页数:10
相关论文
共 50 条
  • [21] Monotherapy with minocycline or trimethoprim/sulfamethoxazole for treatment of Stenotrophomonas maltophilia infections
    Hand, Elizabeth
    Davis, Hannah
    Kim, Ted
    Duhon, Bryson
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2016, 71 (04) : 1071 - 1075
  • [22] Characterization of Stenotrophomonas maltophilia phage AXL1 as a member of the genus Pamexvirus encoding resistance to trimethoprim-sulfamethoxazole
    McCutcheon, Jaclyn G.
    Lin, Andrea
    Dennis, Jonathan J.
    SCIENTIFIC REPORTS, 2022, 12 (01)
  • [23] Trimethoprim/sulfamethoxazole pharmacodynamics against Stenotrophomonas maltophilia in the in vitro chemostat model
    Lasko, Maxwell J.
    Tabor-Rennie, Jennifer L.
    Nicolau, David P.
    Kuti, Joseph L.
    JOURNAL OF ANTIMICROBIAL CHEMOTHERAPY, 2022, 77 (11) : 3187 - 3193
  • [24] Sulfamethoxazole/trimethoprim versus fluoroquinolones for the treatment of Stenotrophomonas maltophilia bloodstream infections
    Watson, Lucas
    Esterly, John
    Jensen, Ashley O.
    Postelnick, Michael
    Aguirre, Arturo
    McLaughlin, Milena
    JOURNAL OF GLOBAL ANTIMICROBIAL RESISTANCE, 2018, 12 : 104 - 106
  • [25] Evaluation of trimethoprim-sulfamethoxazole based combination therapy against Stenotrophomonas maltophilia: in vitro effects and clinical efficacy in cancer patients
    Araoka, Hideki
    Baba, Masaru
    Okada, Chikako
    Abe, Masahiro
    Kimura, Muneyoshi
    Yoneyama, Akiko
    INTERNATIONAL JOURNAL OF INFECTIOUS DISEASES, 2017, 58 : 18 - 21
  • [26] Risk factors for hospital acquisition of trimethoprim-sulfamethoxazole resistant Stenotrophomonas maltophilia in adults: A matched case-control study
    Wang, Ching-Hsun
    Lin, Jung-Chung
    Chang, Feng-Yee
    Yu, Ching-Mei
    Lin, Wei-San
    Yeh, Kuo-Ming
    JOURNAL OF MICROBIOLOGY IMMUNOLOGY AND INFECTION, 2017, 50 (05) : 646 - 652
  • [27] INVITRO SUSCEPTIBILITY OF PSEUDOMONAS-CEPACIA AND PSEUDOMONAS-MALTOPHILIA TO TRIMETHOPRIM AND TRIMETHOPRIM-SULFAMETHOXAZOLE
    MOODY, MR
    YOUNG, VM
    ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 1975, 7 (06) : 836 - 839
  • [28] Comparison of Doxycycline or Minocycline to Sulfamethoxazole-Trimethoprim for Treatment of Stenotrophomonas maltophilia Pneumonia
    Alhayani, Taha
    Philpott, Carolyn D.
    Liao, Siyun
    Gentene, Anthony J.
    Mueller, Eric W.
    ANNALS OF PHARMACOTHERAPY, 2024, 58 (01) : 21 - 27
  • [29] Synergy of colistin with rifampin and trimethoprim/sulfamethoxazole on multidrug-resistant Stenotrophomonas maltophilia
    Giamarellos-Bourboulis, EJ
    Karnesis, L
    Giamarellou, H
    DIAGNOSTIC MICROBIOLOGY AND INFECTIOUS DISEASE, 2002, 44 (03) : 259 - 263
  • [30] Activity of trimethoprim/sulfamethoxazole plus polymyxin B against multiresistant Stenotrophomonas maltophilia
    Munoz, JL
    Garcia, MI
    Munoz, S
    Leal, S
    Fajardo, M
    GarciaRodriguez, JA
    EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 1996, 15 (11) : 879 - 882